Seeking Alpha

New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life

ABBOTT PARK, Ill., Oct. 6, 2022 /PRNewswire/ -- A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's ...
Nasdaq

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also ...
NBC4 Columbus

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...